Catalog No.
DVV03602
Expression system
Mammalian Cells
Species reactivity
Zaire ebolavirus (ZEBOV)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Envelope glycoprotein, GP1,2, GP, Shed GP, GP1,2-delta, GP1, GP2, GP
Concentration
2.53 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q05320
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN-3470-3471-3479, REGN-3470/REGN-3471/REGN-3479, REGN-EB3, REGNEB3, Inmazeb (atoltivimab, maftivimab, odesivimab-ebgn), CAS: 2135632-30-1
Clone ID
Odesivimab
Note
For research use only. Not suitable for clinical or therapeutic use.
Atoltivimab, Maftivimab, and Odesivimab-ebgn., PMID:33354710
REGN-EB3: First Approval., PMID:33432551
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma., PMID:34335620
Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus., PMID:34405205
A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease., PMID:34563987
Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program., PMID:34587535
Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus., PMID:34632543
Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development., PMID:35082794
A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020., PMID:35085865
Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020., PMID:35320651
Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis., PMID:35803293
A drug-disease model for predicting survival in an Ebola outbreak., PMID:35895082
Structure of the Inmazeb cocktail and resistance to Ebola virus escape., PMID:36708708
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma, PMID: 34335620
Inmazeb, PMID: 33497162
Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus, PMID: 34405205
REGN-EB3: First Approval, PMID: 33432551
Atoltivimab, Maftivimab, and Odesivimab-ebgn, PMID: 33354710
For research use only. Not for human or drug use.
